<DOC>
	<DOCNO>NCT00496782</DOCNO>
	<brief_summary>The purpose pilot study determine whether correlation viral load reduction ( Day 4 , 7 14 ) follow short course ( 14 day ) Maraviroc add fail regimen , R5 result TrofileTM assay screening .</brief_summary>
	<brief_title>Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay</brief_title>
	<detailed_description>The study A4001060 discontinue April 22 , 2008 . A review poor rate enrollment project difficulty complete study timely manner , despite best effort sponsor site . Given difficulty encounter pilot study need conduct even large confirmatory study , decision discontinue study therefore make . It note safety concern see study factor decision .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>≥ 16 year age ( minimum adult age determine local regulatory authority dictate local law ) screen visit . Have HIV RNA ≥ 1000 copies/mL , screen . Subjects receive another investigational antiretroviral compound participation phase 3 4 clinical study eligible participate trial provide . That 2 investigational agent require offer subject regimen 2 3 active antiretroviral drug ( i.e . one few approve treatment available subject due prior resistance intolerance ) , Neither protocol prohibits use antiretroviral agent , AND dose two agent use together know AND letter Pfizer clinical pharmacologist maraviroc identifies dose maraviroc use investigational agent . Based screen genotypic resistance test result subject must able receive least 3 active drug maraviroc new OBT . This define : Having three drug consider susceptible genotype interpretation ( etravirine use , few 3 etravirine resistance mutation take etravirine susceptibility ) ; , Having two drug consider susceptible genotype interpretation ( etravirine use , few 3 etravirine resistance mutation take etravirine susceptibility ) willing include raltegravir OBT use raltegravir past . Potentially life threatening ( Grade 4 ) laboratory abnormality medical condition . Severe hepatic impairment ( ChildPugh classification B C ) . End stage renal disease disease state require dialysis therapy .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>